Vibecotamab: A Potential Treatment Option for Myeloid Blood Cancers

Vibecotamab is a type of antibody designed to target a specific protein called CD123, which is found in high levels on cancerous blood cells, especially those that affect the bone marrow’s ability to produce healthy blood cells (myeloid disorders). Because normal blood-forming cells have much lower levels of CD123, targeting this protein may help eliminate cancerous cells while sparing healthy ones.

A recent clinical study evaluated vibecotamab in patients with myeloid disorders who had limited treatment options. The study included patients with:

• Myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) who have not responded to previous hypomethylating agents (azacitidine, decitabine).

• Acute myeloid leukemia (AML) and in remission but with minimal residual disease (MRD) positive, meaning small amounts of leukemia cells remained in the body despite initial treatment.

Key Study Findings

Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia

• 68% of patients showed improvement
• 63% achieved complete remission, meaning cancerous cells were no longer detectable in the bone marrow
• It is particularly telling that all 3 patients with CMML achieved a complete remission
• The median duration of response was 5.2 months
• Patients in the study lived for about 10 months on average after starting the treatment

Acute Myeloid Leukemia 

• 28% of patients achieved MRD negativity, meaning there were no detectable leukemia cells in the bone marrow.
• All responses happened within the first treatment cycle.
• Some patients maintained their remission for over two years, while others relapsed after stopping treatment.
• There was no connection between how likely someone was to respond and the amount of CD123 expressed in cancer cells.

What’s the Safety Profile of Vibecotamab?

• Vibecotamab was considered by the researchers to be generally well tolerated
• The most common side effect was infusion-related reactions, which were mostly mild to moderate
• No patients had to stop treatment due to severe side effects
• Unlike some other treatments, vibecotamab caused minimal suppression of healthy blood cell production

What This Means for Patients

The study suggests that vibecotamab may be beneficial for patients with limited treatment options, especially those with high-risk or relapsed disease. The findings suggest continuing vibecotamab beyond the initial treatment period may help maintain remission.

If you or a loved one is exploring new treatment options, it may be helpful to discuss new agents being tested in clinical trials. They can assess whether a new treatment like vibecotamab may be appropriate based on your specific condition, previous treatments, and overall health.

If you want to read more about treatment advances and clinical trial updates, bookmark the HealthTree News page to browse our articles, written just for you! 

Keep Reading More Articles